Intestinal microecology-based treatment for inflammatory bowel disease: Progress and prospects.
World J Clin Cases
; 11(1): 47-56, 2023 Jan 06.
Article
in English
| MEDLINE | ID: covidwho-2246511
ABSTRACT
Inflammatory bowel disease (IBD) is a chronic, recurrent, and debilitating disorder, and includes Crohn's disease and ulcerative colitis. The pathogenesis of IBD is closely associated with intestinal dysbiosis, but has not yet been fully clarified. Genetic and environmental factors can influence IBD patients' gut microbiota and metabolism, disrupt intestinal barriers, and trigger abnormal immune responses. Studies have reported the alteration of gut microbiota and metabolites in IBD, providing the basis for potential therapeutic options. Intestinal microbiota-based treatments such as pre/probiotics, metabolite supplementation, and fecal microbiota transplantation have been extensively studied, but their clinical efficacy remains controversial. Repairing the intestinal barrier and promoting mucosal healing have also been proposed. We here review the current clinical trials on intestinal microecology and discuss the prospect of research and practice in this field.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Language:
English
Journal:
World J Clin Cases
Year:
2023
Document Type:
Article
Affiliation country:
Wjcc.v11.i1.47
Similar
MEDLINE
...
LILACS
LIS